ATYR Insider Trading Activity and SEC Form 4 Filings
ATYR insider trading summary
Over the past 12 months, insiders at aTYR PHARMA INC (ATYR) reported 3 sales worth $6K by 3 insiders and 1 open-market purchase worth $50K by 1 insider on SEC Form 4. Net insider buying was $43K.
Latest ATYR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 27, 2026 | Paul Schimmel | Insider | Buy | $50K (100,000 @ $0.50) |
| Feb 4, 2026 | Nancy Denyes | General Counsel | Sell | $1K (1,118 @ $0.98) |
| Feb 4, 2026 | Sanjay Shukla | President and CEO | Sell | $4K (3,745 @ $0.98) |
| Feb 4, 2026 | Jill Marie Broadfoot | Chief Financial Officer | Sell | $2K (1,558 @ $0.98) |
| Oct 9, 2025 | Paul Schimmel | Insider | Buy | $299K (317,999 @ $0.94) |
| Oct 8, 2025 | Paul Schimmel | Insider | Buy | $612K (682,001 @ $0.90) |
| Mar 17, 2025 | Jane A Gross | Insider | Buy | $15K (3,750 @ $4.00) |
| Feb 4, 2025 | Jill Marie Broadfoot | Chief Financial Officer | Sell | $5K (1,254 @ $3.78) |
| Feb 4, 2025 | Nancy Denyes | General Counsel | Sell | $3K (899 @ $3.78) |
| Jul 24, 2024 | Paul Schimmel | Insider | Buy | $101K (52,300 @ $1.93) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.